A New Treatment For Crohn’s Disease

(Posted on Tuesday, February 17, 2026)

A new approach to Crohn’s disease is based on genetic analysis of the immune response. The genetic analysis reveals that altering the activity of a specific immune regulator subtly dampens the immune response, offering potential relief for those suffering from Crohn’s disease. A new drug, compound 6, does just that. Clinical trials are currently underway. This is an early, concrete example of how reading our genetic code can lead to safer, more durable, and more precisely targeted treatments for many diseases in the future.

The Basics of Crohn’s Disease

Crohn’s disease is a long-term condition in which the immune system mistakenly attacks the digestive tract, causing ongoing inflammation. This inflammation can affect any part of the digestive system, but most often involves the small intestine and the beginning of the large intestine. The exact cause of Crohn’s disease is not fully understood. It is thought to result from a combination of genetic factors, environmental influences and abnormal immune responses. Crohn’s disease can occur at any age and often requires ongoing medical care to manage symptoms and prevent complications.

Most Crohn’s therapies today work from the outside in. Current treatments work by blocking the signals that trigger inflammation throughout the body. Some of the most advanced medicines, called biologics, are made from living cells. These medicines use specific proteins, called antibodies, to block certain components of the immune system. Some biologics block tumor necrosis factor, a cytokine that increases inflammation, or interleukin-23, a cytokine that promotes immune cell communication and can drive inflammation.

Newer oral medicines target different pathways in immune cells. Still, 40-60% of patients do not respond or stop benefiting over time. These treatments have transformed care, but up to half of patients either never respond or lose response over time, and all carry some increased risk of infection because they dampen large parts of the immune system.

One of The Genes Behind Crohn’s Disease

Human genetics offers a more tailored starting point. The caspase recruitment domain‑containing protein 9, or CARD9, is an adaptor protein that resides in innate immune cells and helps them respond to microbes in the gut, especially fungi, by transmitting signals from pattern‑recognition receptors at the cell surface to inflammatory pathways within the cell.

When these receptors sense fungal or other microbial components, CARD9 helps assemble signaling complexes that recruit and activate other immune cells. In this way, CARD9 shapes both the composition of the gut microbiota and the intensity of intestinal immune responses. It has been identified as a key gene for inflammatory bowel disease. People who completely lack functional CARD9 suffer from recurrent, often life‑threatening fungal infections, underscoring how essential this pathway is for antifungal defense.

Genetic studies show that different CARD9 variants push disease risk in opposite directions. Certain common variants are associated with heightened activity, exaggerated inflammatory signaling, and increased susceptibility to Crohn’s disease and ulcerative colitis. By contrast, a rare variant produces a shortened protein that cannot fully engage, leading to reduced CARD9 signaling.

Individuals who carry even a single copy of this truncated variant are protected against Crohn’s disease and ulcerative colitis, yet they retain enough CARD9 function to handle everyday infections, suggesting that partial down‑modulation of the pathway can lower risk without completely disarming the immune system. In other words, their immune response is gently tuned down rather than switched off, making CARD9 a genetic dial for calibrating intestinal inflammation.

A Starting Point for Genetic Medicine

The new work turns this natural experiment in human genetics into a therapeutic roadmap. A small structural pocket in CARD9 is critical for its ability to bind partner proteins and relay activating signals. Guided by the protective variant, large chemical libraries were screened for small molecules that could nestle into this pocket, subtly destabilize the active signaling complex and hold CARD9 in a “quiet” state. The aim was not to knock the gene out entirely—which would increase susceptibility to invasive fungal disease—but to reduce its aggressiveness.

From this effort, compound 6 emerged as the most promising drug candidate. In preclinical studies, compound 6 selectively dampened CARD9‑dependent signaling when immune cells encountered fungal components. At the same time, it left CARD9‑independent pathways, such as those triggered by other receptors and adaptor proteins, largely intact, allowing the immune system to continue performing many of its normal protective functions.

Therefore, instead of flipping the gene fully on or off, the molecule binds and stabilizes it in a restrained configuration that closely mimics the effect of the natural protective variant in people. These findings show that a single, genetics‑guided small molecule can safely turn down an overactive Crohn’s pathway. This delivers targeted anti‑inflammatory effects while preserving much of the immune system’s normal protective work.

A Roadmap for Translating Genetics to Medicine

Genetic studies have already uncovered hundreds of gene variants that either increase or decrease the risk of common diseases; until now, many targets have been considered “undruggable” because they are not classic enzymes. The CARD9 work shows that even these difficult proteins can be tamed with chemistry. Also, a protective gene variant can serve as a blueprint for designing drugs that shift biology in the same direction.

If this strategy can be repeated for other genes and diseases, the impact could extend far beyond Crohn’s. As we learn to translate the instructions embedded in our DNA, we gain the ability to create therapies that are safer, longer-lasting, and uniquely tailored to each individual. While further research is needed before these new medicines can be used alongside current Crohn’s therapies, the approach signals a shift from one-size-fits-all treatments to a future where precision, durability and personalization are the norm.